Abu Dhabi to Host 2nd Investopia Annual Conference in 2023
22.9.2022 14:27:00 EEST | Business Wire | Press release
Abu Dhabi will host the second Investopia annual conference on 1 - 2 March 2023, under the theme ‘envisioning opportunities in times of change’, in collaboration with Abu Dhabi Department of Economic Development (ADDED).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005469/en/
H.E. Abdulla Bin Touq Al Marri, UAE Minister of Economy during Investopia 2023 Launch Event (Photo: AETOSWire)
Investopia 2023 date has been announced by H.E. Abdulla Bin Touq Al Marri, UAE Minister of Economy, during a business session organised by Investopia and ADDED in Abu Dhabi, attended by Investopia partners, senior officials, and CEOs from public and private sectors.
Investopia 2023 will discuss the shifts in the global investments amid developments that have created new economic concepts related to virtual reality, sustainable and green economy.
H.E. Bin Touq said: "The challenges currently facing global economies have highlighted the strategic need to develop more solutions through new economic sectors capable of meeting the requirements of sustainable development and generating growth opportunities. Investopia annual conference, in its new edition next year, will address a new generation of investment opportunities in transport technology, climate, food and energy, which have become a real bet for sustainable development and basic pillars of future economies.”
H.E. Bin Touq underlined that the UAE has set an ambitious goal for the next 50 years to transition to a new development model that is more open to the world and based on advanced technologies, talents, creativity and emerging ideas. He noted that Investopia is one of the leading initiatives that supports the national ambitions, provides a new space to promote global investment dialogue, and contribute to the launch of innovative ideas that create new and sustainable growth opportunities.
H.E. Mohamed Ali Al Shorafa, Chairman of ADDED, said: “co-organising the second edition of the Investopia conference is in line with our efforts to further build on the UAE’s reputation as a global investment hub, and cements Abu Dhabi’s position as an active and thriving and preferred business hotspot”.
“Abu Dhabi has nurtured a supportive business environment, unparalleled connectivity and infrastructure, and an entrepreneurial mindset that presents investors with growth opportunities. We believe Investopia, which is one of the major strategic initiatives under the ‘Projects of the 50’, is the right platform to discuss current and future economic trends and ways to enhance our national economy's competitiveness,” H.E. Al Shorafa concluded.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005469/en/
Contact information
Wajd Breek
wbreek@golin-mena.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release
Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila
PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom